Prosecution Insights
Last updated: July 17, 2026

Signpath Pharma Inc.

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

3
Total Pending OAs
3
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (67%)
1
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (33%)
§102 only1 (33%)
§112 only1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
O DELL, DAVID K 1 57.6% +36.1%
RODRIGUEZ, RAYNA B 1 33.0% +20.6%
RONEY, CELESTE A 1 62.6% +17.8%

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18457037 CARDIOPROTECTIVE LIPIDS AND METHODS OF USE O DELL, DAVID K
18260012 LIPIDS THAT REDUCE LUNG DAMAGE, IMPROVE PULMONARY FUNCTION AND DECREASE PRO-INFLAMMATORY CYTOKINES RODRIGUEZ, RAYNA B
16433555 Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier Current RONEY, CELESTE A

Top Art Units

Art UnitApps
1621 1
1628 1
1612 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18457037 CARDIOPROTECTIVE LIPIDS AND METHODS OF USE O DELL, DAVID K 1621 §102 Non-Final OA Pending Aug 28, 2023
18260012 LIPIDS THAT REDUCE LUNG DAMAGE, IMPROVE PULMONARY FUNCTION AND DECREASE PRO-INFLAMMATORY CYTOKINES RODRIGUEZ, RAYNA B 1628 §103 Non-Final OA Pending Jun 29, 2023
16433555 Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier Current RONEY, CELESTE A 1612 §112 Non-Final OA Pending Jun 06, 2019

Managing Signpath Pharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month